The FDA on February 6, 2019 approved CABLIVI® for adult patients with acquired Thrombotic Thrombocytopenic Purpura (aTTP), in combination with Plasma Exchange and immunosuppressive therapy. CABLIVI® is a product of Ablynx NV.
Bottom Ad
Advertisement
Subscribe
